Background: Levodopa and dopamine agonists (dopamine replacement therapy, DRT) are implicated in Parkinson's disease psychosis (PDP) but the relationship between DRT and neurotransmitter dysfunction inherent to PD remains unclear.
Visual hallucinations, illusions and delusions occur at some point in most patients with Parkinson's disease (PD) [1] -a spectrum referred to collectively as PD psychosis (PDP) [2] . PDP reduces quality of life [3] , while increasing carer distress [4] and the risk of care home placement [5] . Treatment has proved challenging as the underlying cause remains unclear. Although recent research has focussed on cholinergic [6] and serotonergic [7] mechanisms, clinical experience suggests PDP is associated with the start or dose change of levodopa or dopamine agonist medication (dopamine replacement therapy -DRT), with the first line of treatment a reduction in medication. Studies of dopamine transporter (DAT) striatal binding have found patients susceptible to PDP have lower binding compared to those that are not [8] [9] [10] , implicating dopamine in the PDP mechanism. However, the studies have not addressed the possibility that a striatal dopamine deficit may lead to differences in subsequent DRT prescribing, leaving open the possibility that the DRT regime causes PDP, not the dopamine deficit itself. Alternatively, the greater dopamine deficit may mark patients with a receptor up-regulation and dopamine hypersensitivity, with PDP triggered by first DRT exposure or a specific DRT dose threshold.
Here we set out to address these issues by examining DAT striatal binding and PDP using the finegrain clinical detail of the Parkinson's Progression Markers initiative [11] . Excluding patients with idiopathic PD who had already developed PDP at the time of PPMI entry, we compared DAT striatal binding in patients who went to develop PDP with those that did not, taking into account their prospective DRT prescribing history and examining drug regime and dose changes with respect to PDP onset at a level of detail not possible in previous studies. As patients are recruited to PPMI when drug naïve, we avoided the possible influence of DRT on striatal DAT binding by focussing our analysis on the baseline study entry scans.
Methods
• PDP+ Patients with hallucinations or delusions (score of 2, 3 or 4 on the UPDRS part1 hallucinations/psychosis item) at one or more follow-up visits but not the baseline or screening visit. • PDP-Patients without hallucinations or delusions at baseline or any subsequent visit for a minimum follow-up duration of 30 months (score of 0 or 1 on the UPDRS part1 hallucinations/psychosis item).
Results
386 patients with DAT-confirmed idiopathic PD were identified for further analysis. Of these, 30 patients experienced formed hallucinations or delusions at one or more time points (PDP+) following the baseline visit. One patient reported hallucinations at baseline and was excluded from the DAT scan analysis. The mean onset of PDP was 42 ± 20 months (range 4 -85) after baseline. None of the PDP+ group had significant eye disease (n=20 refractive error or presbyopia; n=2 cataracts). The most common PDP symptoms were: 'formed hallucinations with insight' (n=19); 'formed hallucinations without insight' (n=8) and delusions (n=3). Illusions were reported in 87% (26/30) of the PDP+ group at one or more visits. 355 patients had no reports of formed hallucinations or delusions (PDP-) over a mean follow-up duration of 64 ± 11 months (range 31 -88 months). 31% of the PDP-group (111/355) reported illusions at one or more visit. Table 1 shows the baseline characteristics of PDP+ and PDP-groups.
Baseline mean total striatal DAT binding was reduced in the PDP+ group compared to PDP-in both the model using LEDD as an index of prospective DRT (F(1,377) = 10.9; p=0.001) and the model using binary dopamine agonist and levodopa variables (F(1,375) = 10.06; p = 0.002). The results remained significant when repeated with the three patients who developed delusions excluded. The effect size was greater for the caudate subregion than the putamen subregion (mean caudate β = 0.333; mean putamen β = 0.139), and greater in the right caudate nucleus than the left (right caudate β = 0.363; left caudate β = 0.303). There was no significant difference in DAT binding between patients who did and did not develop illusions in the PDP-group (F(1,339) = 0.007; p = 0.93).
DRT medication history
At the time of data download, almost all patients (98%) were prescribed DRT, but only 8% had developed PDP. Figure 1 shows the DRT history of the PDP group, categorised by regimen at the time of PDP onset. 5 patients (6 including the patient with hallucinations at baseline -19%) developed symptoms when not on DRT. The relationship of PDP onset to DRT in two further patients (H02 and H11) is unclear, as both occurred in the same month and the exact event sequence is not recorded in the database. Eight patients developed PDP in the context of treatment with levodopa only (mean exposure 32±19 months at PDP onset). Four patients developed PDP during treatment with a dopamine agonist only (mean exposure 25±10 months at PDP onset). Seven patients developed PDP on combined dopamine agonist and levodopa (mean exposure for combined medications 25±13 months; mean exposure of first medication 40±10 months at PDP onset). Four patients had complex prior medication histories (mean exposure 54±16 months at PDP onset).
The temporal relationship between PDP onset and medication dose change was examined in the levodopa group. Of the 8 patients in the levodopa group, 5 were on a stable regime for at least 4 months before hallucination onset (range 4 -20 months). One patient had a reduction in levodopa in the same month as PDP onset, likely to have been instituted as a management strategy for PDP. Levodopa dose increase may have coincided with PDP onset in two patients, although the sequence of events is not recorded in the database.
Discussion
Most patients in the PPMI cohort (92%) have not developed PDP, despite DRT exposure at higher doses and for longer duration than the minority of patients (8%) who have developed them. Mean striatal DAT binding in patients who go on to develop PDP is reduced at baseline compared to pa-tients who do not, controlling for global cognition, motor severity, sex and subsequent DRT exposure. In what follows, we explore the implications of the findings for the respective contribution of disease effects and DRT in the mechanism of PDP.
Striatal DAT binding and Parkinson's psychosis: disease effect
In previous studies, lowest quartile range mean striatal binding has been found to predict several clinical milestones at 5 years, including PDP and cognitive impairment [10] . Furthermore, reduced DAT binding in the right caudate nucleus [8] and ventral striatum [9] may predispose patients to visual hallucinations. We add to these findings by showing reduced striatal DAT binding is independent of a range of clinical and medication-related confounds and add further evidence for a role of the right caudate nucleus in PDP. A similar association has been reported in the PPMI dataset for incident impulse control disorder (ICD) symptoms [12] . The suggestion of greater DAT binding reduction in the right caudate nucleus helps account for inhibitory executive function deficits found in previous studies [13] .
Dopamine medication and Parkinson's psychosis: drug effect
If dopamine medication was the sole cause of PDP, one would not expect incident cases without it. 19% of the PDP group had onset of PDP while not on a dopamine agonist or levodopa. This rate is similar to the 13% of incident ICD behaviors prior to DRT [12] , and highlights the importance of factors other than medication in the development of neuropsychiatric symptoms in PD. Although the majority of patients that developed PDP were prescribed DRT at the time of onset (81%), there was no clear predominance of exposure history for dopamine agonists, levodopa alone or combinations of both. Patients had typically been prescribed DRT for a year or more at PDP onset and had been on a stable regime for 4 months. This suggests PDP is not caused by striatal receptor up-regulation and DRT hypersensitivity, as one would expect such effects to coincide with medication onset or a dose increase.
Limitations
The pathophysiological mechanism underlying hallucinations and delusions may differ in early and late stage PD [14] , so the findings described here may not apply in more advanced disease. Furthermore, the relationship between dopaminergic mechanisms and serotonergic or cholinergic mechanisms has not been assessed. There are also limitations in using the MDS-UPDRS psychosis item to assess PDP, as it does not allow detailed analysis of symptom subtypes and sampling is limited to the week before assessment. Patients in the PDP-group may thus have PDP symptoms outside the sampling period and PDP-and PDP+ groups may therefore be more correctly described as having lower (PDP-) higher (PDP+) rates of PDP rather than PDP being present or absent. The risk factors for PDP in the PPMI cohort may also not be representative of those typical in PD as PPMI participants are relatively younger, cognitively intact and have higher educational achievement than other PD cohorts.
In conclusion, our findings suggest that, alongside medication, dopamine-related disease mechanisms may be involved with other neurotransmitter systems in the hallucinations and delusions of PDP. The same may not be true of illusions. It remains unclear how drug and disease effects interact to cause psychosis in early-stage PD as we did not find support for an association between PDP and a specific DRT regime or for a temporal relationship between PDP onset and DRT onset or levodopa dose increase. 
